Foghorn Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of medicines targeting the chromatin regulatory system. By utilizing its proprietary Gene Traffic Control platform, the enterprise focuses on discovering and developing innovative therapeutics designed to treat severe diseases, particularly oncology indications with high unmet medical needs.